61 results
8-K
EX-99.2
CHRS
Coherus Biosciences Inc
2 Feb 21
Entry into a Material Definitive Agreement
8:45am
) is an innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapeutics. The company has … continuous innovation for disease control and prevention of the global pandemic. Junshi Biosciences has over 2,000 employees in the United States (San
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
13 Jan 22
Entry into a Material Definitive Agreement
4:39pm
-clinical as well as clinical teams at the company’s innovation centers in China and the U.S. We believe the collaboration with Coherus will strengthen … of Avastin® (bevacizumab).
About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HKEX: 1877; SSE: 688180) is an innovation-driven
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
2 Feb 21
Entry into a Material Definitive Agreement
8:45am
-oncology combinations,” said Denny Lanfear, CEO of Coherus. “Junshi Biosciences is an innovation-driven biopharmaceutical company with global clinical … and natural killer (“NK”) cells.
About Junshi Biosciences
Founded in December 2012, Junshi Biosciences (HK: 1877; SH: 688180) is an innovation-driven
DRSLTR
CHRS
Coherus Biosciences Inc
15 Sep 14
Correspondence regarding draft registration statement
12:00am
) biologic pathway with the abbreviated licensure pathway for biosimilars under the Biologics Price Competition and Innovation Act of 2009, or BCPIA … the requirements set out in the Biologics Price Competition and Innovation Act (the “BPCI Act”) and the U.S. Food and Drug Administration (“FDA”) guidance
425
SURF
Surface Oncology, Inc.
16 Jun 23
Business combination disclosure
5:14pm
meeting, and it will be the first immunotherapy option for NPC patients in the US, if approved. We are very proud of the innovation this next-generation PD
8-K
EX-99.1
e2t9c qbwoq9fp4kd
8 May 23
Coherus BioSciences Reports First Quarter 2023 Financial Results and Business Highlights
4:16pm
8-K
EX-99.1
l410lw1rwj a7ugwm77q
2 Aug 23
Coherus BioSciences Reports Second Quarter 2023 Financial Results and Business Highlights
4:05pm
8-K
EX-99.1
hl8omc4jseh7g3569rw
27 Oct 23
Regulation FD Disclosure
4:19pm
DRS/A
EX-10
dali0fhj80u1o0alp
5 Aug 14
Draft registration statement (amended)
12:00am
DRS/A
EX-10
wtxf bdiocx
5 Aug 14
Draft registration statement (amended)
12:00am
DRS
1u7hh3x 70705q26
4 Aug 14
Draft registration statement
12:00am
DRS/A
4gkprb0hhbqy
15 Sep 14
Draft registration statement (amended)
12:00am
S-1/A
zkfeu
6 Oct 14
IPO registration (amended)
12:00am